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Trying to Understand BARI*
SPENCER B. KING III, MD, FACC
Atlanta, Georgia
The Bypass Angioplasty Revascularization Investigation
(BARI) trial is now approaching its tenth year. Soon it will be
a teenager, and we are still trying to understand all the
findings. Not unlike other teenagers, the answers do not come
easily.
Rozenman et al. (1), from Haddasah University Hospital in
Jerusalem, have looked for a solution in their report in this
issue of the Journal. They performed a retrospective review of
55 patients with and 193 without diabetes mellitus who had
follow-up elective coronary arteriograms .1 month after suc-
cessful angioplasty. The goal of the study was to compare the
angiographic progression of coronary disease between the
diabetic and nondiabetic groups and in arteries with versus
without instrumentation. The authors classified advancing
disease into progression of lesions that were initially .20%
and the appearance of new lesions.
Rozenman et al. (1) could not find a significant difference in
restenosis (41% in diabetic and 35% in nondiabetic patients) in
their small series. Likewise, the progression of established
lesions was not different, but the appearance of new narrow-
ings was higher in the diabetic group. They also state that the
new lesions were more common in diabetic patients with
arteries undergoing percutaneous transluminal coronary an-
gioplasty (PTCA) than in arteries not undergoing PTCA
(16.9% vs. 13.2%). The authors conclude that the combination
of diabetes and PTCA of an artery increases the chance of new
lesion formation and may therefore be an explanation for the
excess mortality in the PTCA arm of the BARI trial. Rozen-
man et al. thus raise an important concern about interventional
procedures in diabetic patients.
However, the study (1) falls short of establishing new lesion
formation as the clear explanation of the results of the BARI
trial. Some of the deficiencies of the study (many pointed out
by the authors themselves) include the very small sample size
(55 diabetic patients), the selection for restudy only for elective
indications (which may have blunted the difference in resten-
osis rates) and the somewhat artificial separation of progres-
sion into new lesions and progression of mild lesions. When all
disease progression was combined, the relative difference
decreased. Finally the diabetic patients had narrower nonin-
volved segments than did nondiabetic patients. It is therefore
possible that new lesions actually represent progression from
preexisting diffuse atherosclerotic segments that appear nor-
mal on angiographic examination.
Previous studies (2) have firmly established the increased
risk that diabetic patients face. Other larger observational
studies have also pointed to the adverse long-term outcome of
diabetic patients undergoing PTCA (3) or bypass surgery (4).
Recently, the BARI study (5) showed that the difference in
survival between PTCA and bypass surgery in patients with
multivessel disease was limited to the group with treated
diabetes mellitus. Several explanations are possible and are not
yet completely understood. The procedure could produce a
higher acute complication rate; there could be greater resten-
osis; progression could be more likely in the PTCA cohort; and
overall revascularization could be less in patients undergoing
PTCA who have fewer vascular segments revascularized (6).
The evidence for more abrupt closure after PTCA was not
supported in a study from our institution; however, there was
higher mortality when abrupt closure occurred, as was the case
in the National Heart, Lung, and Blood Institute PTCA
registry (7). We also found a higher restenosis rate in patients
undergoing PTCA (8,9). Diabetes is also a risk factor for late
cardiac events, even after the healing phase of PTCA has been
completed. These continuing clinical events in the diabetic
population suggest continuing progression of disease (10,11).
Other mechanisms, including myocardial and microvascular
abnormalities, may hinder the ability of diabetic patients to
survive coronary occlusion (12).
The randomized trials, particularly BARI and now sup-
ported by the Coronary Angioplasty Versus Bypass Revascu-
larization Investigation (CABRI) (13) but not by the Emory
Angioplasty Versus Surgery Trial (EAST), show excess mor-
tality in the surgical group. A side by side comparison of the
randomized patients in the EAST trial and the patients in the
BARI trial reveals the EAST diabetic patient group to be
somewhat less sick. Another distinguishing feature that may be
important was the mandated protocol angiograms and thallium
scans at 1 and 3 years used in the single-center EAST trial.
Although survival was 90% at 5 years in the EAST trial, only
37% of the PTCA-treated patients were surviving free of
repeat interventions. Heightened surveillance, careful glycemic
control (15), and a search for ischemia may be important
follow-up measures for patients with treated diabetes under-
going multivessel PTCA. Although randomized trials eliminate
bias, they may be difficult to generalize. Patients not in trials
are more commonly referred for bypass surgery if the disease
is far advanced or for PTCA if the disease is more amenable to
that approach. The BARI registry did not show a difference in
survival among the diabetic patients assigned to bypass surgery
or PTCA, and a survey of .2,600 diabetic patients undergoing
PTCA or bypass surgery at Emory University showed no
overall difference in 5-year survival rate (78% for PTCA, 76%
for bypass surgery). The insulin-requiring diabetic patients also
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had a similar 5-year survival rate (72% for PTCA, 70% for
bypass surgery). However, after correction for baseline differ-
ences, the bypass surgery group had slightly better survival.
The question therefore remains whether diabetic patients
selected for PTCA (as opposed to those assigned in random-
ized trials) are subjected to greater risk.
The second point of the study by Rozenman et al. (1) was to
determine whether the arteries undergoing instrumentation
with PTCA devices had a greater risk of disease progression.
The difference between the instrumented and noninstru-
mented arteries of the diabetic patients in this study was very
small (16.9% vs. 13.2%). In the randomized EAST trial with
prospectively performed follow-up quantitative coronary arte-
riography, progression of disease 3 years after the initial proce-
dure was significantly predicted by the presence of diabetes,
among other factors (14). In that study there were no differences
between the instrumented and noninstrumented arteries.
The results of PTCA in diabetic patients have thus far been
tested with balloon technology. Several studies (16–20) have
shown that native coronary arteries and saphenous vein bypass
grafts undergoing stent placement have a restenosis rate that is
significantly influenced by the presence of diabetes. Whether
the randomized trials of stenting versus bypass surgery will
show a difference in the overall clinical outcome between
diabetic and nondiabetic patients remains to be established.
Two trials of stenting versus bypass surgery in Europe (Arterial
Revascularization Therapy Study [ARTS] and Stent or Surgery
[SOS]) will be very interesting regarding the outcome in
diabetic patients. However, if Rozenman et al. are correct in
their hypothesis that progression in nontreated segments is the
major cause of late mortality, this progression will not be
solved by stenting.
The present study adds to our information regarding PTCA
in diabetic patients and prompts further examination of the
influence of the degree of preprocedural narrowing in un-
treated segments on progression but does not solve our
problem completely. Our fractious preteen, BARI, has not
spoken to us regarding the full explanation of why patients
undergoing PTCA did not fare as well as those undergoing
bypass surgery. A current in-depth examination of the 5-year
outcomes in the diabetic population from BARI is in press.
Perhaps as the BARI trial matures, it will be more forthcoming
to the dedicated investigators that study it and to the anxiously
waiting cardiology community.
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